SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.20-5.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (4261)7/9/2001 11:07:52 AM
From: Biomaven  Read Replies (2) of 52153
 
I added to my KOSN this morning near the open. Their dEPOb is really looking like a "better Taxol" in preclinical models, and also seems better than one of the variants BMY has advanced into Phase I trials.

Message 16047422

KOSN is an interesting (but very early stage) company aside from the dEPOb play. Reminds me of SEPR in a way - tinkering with existing molecules (but in a more sophisticated [and hence riskier] manner than SEPR) to try to get improvements.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News